Scientific American – “Current monoclonal antibodies fail against COVID virus variants, so drugmakers want to use a fast-track test for new ones…In an e-mail to Scientific American, an FDA spokesperson said the agency is concerned as well, and it will work with drug companies on expedited development of preventive therapies for immunosuppressed patients. But the… Continue Reading